• Cluster eligibility

‣ Within 8 hours transport of Iquitos

⁃ Incidence \<250/1000 and \>2 cases year prior to trial

⁃ Population size (\<650)

• Chloroquine (CQ) eligibility

‣ Resides in neighboring household but within 200 m of Pv index case in the past 2 years

⁃ Age ≥6 months old

⁃ Present for intervention

⁃ Adult ≥18 years old that provides informed consent

⁃ A child ≥8 years and \<18 years old that provides informed assent and has informed consent from their parents

⁃ A child ≥6 months old and \<8 years old that has informed consent from their parents

• Tafenoquine (TQ) eligibility

‣ Eligible to receive CQ

⁃ Age ≥16 years old

⁃ Adult ≥18 years old that provides informed consent

⁃ A child ≥16 years and \<18 years old that provides informed assent and has informed consent from their parents

• Primaquine eligibility

‣ Eligible to receive CQ and ineligible to receive TQ

⁃ Age ≥6 months old

⁃ Adult ≥18 years old that provides informed consent

⁃ A child ≥8 years and \<18 years old that provides informed assent and has informed consent from their parents

⁃ A child ≥6 months old and \<8 years old that has informed consent from their parents

• Baseline evaluation and informed consent

⁃ Villagers will be eligible to participate in surveys if they slept in a household in cluster randomized to control or focal mass drug administration (fMDA) for at least one night in the past four weeks

• Eligibility for fMDA

‣ High-risk villagers are defined as individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household) will be eligible to receive fMDA that cycle

⁃ Villagers that were eligible but missed in the 1st round in a cycle, or become eligible in the next two months, will not be eligible to receive fMDA in the 2nd round in a cycle.